Advanced Chitosan-Based Nanotherapeutics for the Targeted Treatment of Inflammatory Bowel Disease: From Enzyme Switching to ROS-Responsive Delivery
발표자
이동윤 (한양대학교)
연구책임자
이동윤 (한양대학교)
공동저자
이동윤 (한양대학교)
초록
내용
Conventional oral therapies for Inflammatory Bowel Disease (IBD) are frequently limited by low bioavailability, lack of target specificity, and systemic toxicity. To address these challenges, this study presents the development of three novel mucoadhesive nanotherapeutic platforms—Aurozyme, COS-GL, and the Glyro system—designed to target the inflamed intestinal microenvironment. First, Aurozyme utilizes an amine-rich glycol chitosan coating to switch the activity of gold nanoparticles from peroxidase-like to catalase-like, effectively converting toxic reactive oxygen species (ROS) into water and oxygen. Second, COS-GL nanoparticles, self-assembled from chitosan oligosaccharide and glycyrrhizin, function as immune modulators that promote the repolarization of pro-inflammatory M1 macrophages to the reparative M2 phenotype and restore intestinal barrier integrity. Third, the Glyro system employs a thioketal linker to achieve ROS-responsive drug release, ensuring that therapeutic agents are liberated exclusively within oxidative lesions. In murine colitis models, all three platforms demonstrated superior mucosal retention and therapeutic efficacy compared to standard 5-aminosalicylic acid (5-ASA) treatments. By combining precise oxidative stress regulation, targeted drug delivery, and microbiome restoration, these chitosan-based nanomedicines offer a transformative strategy for achieving sustained remission and mucosal healing in IBD.